About Us
Mission RNAi Management Team Board of Directors Scientific Advisory Board
Board of Directors
Dr. Topper became the chairman of the board of Intradigm in May 2006 following series A financing of the company. Dr. Topper is a general partner at Frazier Healthcare Ventures' Palo Alto office. Since joining Frazier Healthcare in 2003, Dr. Topper has led several biopharma investments including Arête Therapeutics, Cotherix, and MacuSight. Dr. Topper is also an advisory board member to the Harvard-Partners Center for Genetics and Genomics. Prior to joining Frazier Healthcare, he served as head of the cardiovascular research and development franchise at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics). Prior to the merger of COR and Millennium, he served as the Vice President of Biology at COR and was responsible for managing all of its research activities.
Dr. Topper received his MD and Ph D in Biophysics from Stanford University School of Medicine in 1991. He completed his postgraduate training in Internal Medicine and Cardiovascular Disease at the Brigham and Women's Hospital in Boston and is board certified in both disciplines. While there, he completed a research fellowship in the Vascular Research Division in the department of Pathology. He then joined the faculty of Harvard Medical School from 1997 to 1998, and subsequently Stanford University as an Assistant Professor of Medicine (Cardiovascular) in July 1998. He has authored over 50 publications and was the recipient of a Howard Hughes Scholars Award while on the faculty at Stanford University. He continues to hold an appointment as a Clinical Assistant Professor of Medicine at Stanford University.
Dr. Mack joined Intradigm's board in May 2006. He is a director at Alta Partners where he led the investment in Angiosyn as a director and acting CEO (acquired by Pfizer in 2005). He is currently on the board of directors of Aerie Pharmaceuticals, Ceregene and Proacta. Prior to Alta, Dr. Mack co-founded and served as Vice President of Genomics Research at Eos Biotechnology (acquired by Protein Design Labs in 2003). From 1995 to 1997, he served at Affymetrix as Head of Cancer Biology where he oversaw the development and application of DNA array technology in the areas of oncology and inflammation. He was also a pivotal member of the Polymerase Chain Reaction (PCR) invention group at Cetus (now Chiron) in the mid 1980s.
Dr. Mack has co-authored more than 30 scientific articles and reviews, including papers published in Cell, Science and Nature, and he is an inventor on 21 US patents. He was an American Cancer Society postdoctoral fellow at Stanford University School of Medicine in Microbiology and Immunology. Dr. Mack received his Ph.D. in 1992 from the University of Chicago where he was a Howard Hughes fellow in Molecular Genetics and Cell Biology. He holds a Bachelor of Arts in Molecular Biology from University of California, Berkeley.
Dr. Azab joined Intradigm in July 2006. He brings more than 20 years of experience in pharmaceutical drug development. Dr. Azab’s prior appointment was Chief Medical Officer and Executive VP of R&D at QLT Inc, in Vancouver, BC, Canada. Dr. Azab also worked as Entrepreneur In Residence (EIR) for Ventures West, one of Canada’s leading venture capital firms in Technology & Life Sciences. His past positions included leadership of medical oncology at Sanofi Pharmaceuticals (now Sanofi-Aventis) working near Paris, France, and leadership of the clinical drug development in oncology at Zeneca Pharmaceuticals (now Astra Zeneca) in the company’s R&D facility in Macclesfield, England. During his career, he led drug development programs that resulted in the approval and marketing of seven different new chemical entities in the therapeutic areas of oncology, gastroenterology, urology, and ophthalmology including Casodex®, Arimidex®, Faslodex®, Photofrin®, and Visudyne®. Dr. Azab received his medical degree from Cairo University in 1979. He practiced as a medical oncologist at Institute Gustave Roussy, Villejuif, France where he received post-graduate training and degrees from the University of Paris-Sud and the University of Pierre and Marie Curie. He authored more than 100 scientific papers, abstracts, and book reviews.
Dr. Azab also holds an MBA degree with distinction from the Richard Ivey School of Business, University of Western Ontario in Canada. He is a member of the board for Xenon Pharma Inc. as well as Chemokine Therapeutics.
|
